NEXENTIS TECHNOLOGIES INC
NXTSNASDAQTrading Snapshot
- Day Range
- $1.39 – $1.42
- 52-Week Range
- $1.14 – $49.00
- Volume
- $6.84B
- Avg Volume
- $8.85B
- Shares Outstanding
- 1.4M
- Next Earnings
- Nov 24, 2026
Fundamentals Snapshot
- Annual Revenue
- $208,521
- Last Q Revenue
- $47,215
- P/E Ratio
- —
- P/S Ratio
- 10.2x
- EPS (TTM)
- $-55.49
- Dividend Yield
- —
- Dilution (1yr)
- +14.5%
Why Investors Own NXTS
- ✓High-growth profile — revenue up +4.8% YoY with expanding US Equity exposure.
- ✓Healthy economics — 27% gross margin and 18% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
NEXENTIS TECHNOLOGIES INC
NXTS
StockOtter · stockotter.spaceAbout NEXENTIS TECHNOLOGIES INC
Nexentis Technologies Inc., through its subsidiary, develops therapeutics related to cancer and inflammatory metabolic diseases. It operates through two segments, Biotechnology Activity and Renewable Energy Projects. The company's pipeline includes MITOLINE, an algorithm used to perform multiple sequence/ structure pairwise alignments which could then be used for generating a 3D comparative model of potentially all mitochondrial carrier proteins; cloud-based computational chemistry platform; and novel in-vitro screening platforms; and advanced 3D NSCLC tumor spheroid systems.The company was formerly known as N2OFF, Inc. and changed its name to Nexentis Technologies Inc. in February 2026. Nexentis Technologies Inc. was incorporated in 2009 and is headquartered in Ness Ziona, Israel.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
Nexentis: MitoCareX Strengthens Its Computational Drug Discovery Capabilities with Appointment of Prof. Dan T. Major to Scientific Advisory Board
Leading computational chemistry expert to advise MitoCareX as it expands its in silico drug-discovery capabilities Ness Ziona, Israel, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (“Nexentis”), (NASDAQ:
Nexentis: MitoCareX Evaluates Expanded Protein Capabilities to Enhance Flexibility and Support Future Drug Discovery
Evaluation of additional commercially available approaches for obtaining proteins is intended to enhance access to research materials, increase research flexibility and support the advancement of MitoCareX's future in-vi
Nexentis Technologies Subsidiary MitoCareX Bio Selects Transport Protein Candidate for Drug Discovery Campaign
Following its broad structural analysis of the human SLC transport protein family, MitoCareX advances from a pool of candidates to a prioritized target, reflecting continued execution of its MITOLINE ® -driven discovery
Nexentis Subsidiary MitoCareX Bio Advances SLC Transporter Drug Discovery with Broad Analysis and International AI Initiative
MitoCareX Bio completes comprehensive SLC transport protein analysis to support discovery of small molecules for hard-to-treat cancers and inflammatory metabolic diseases and enters an AI-driven small-molecule discovery
Nexentis Announces Monetization of Part of its Melz Solar Investment at $14.5 Million Project Valuation – Significant Premium to Initial Investment
Neve Yarak, Israel, June 29, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS) (“Nexentis” or the “Company”), a drug discovery company that also invests in solar energy assets based on the RTB (Ready to